Marker Therapeutics Stock Alpha and Beta Analysis
| MRKR Stock | USD 3.19 0.07 2.15% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Marker Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Marker Therapeutics over a specified time horizon. Remember, high Marker Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Marker Therapeutics' market risk premium analysis include:
Beta 2.49 | Alpha (0.25) | Risk 7.33 | Sharpe Ratio 0.0199 | Expected Return 0.15 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Marker |
Marker Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Marker Therapeutics market risk premium is the additional return an investor will receive from holding Marker Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Marker Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Marker Therapeutics' performance over market.| α | -0.25 | β | 2.49 |
Marker Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Marker Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Marker Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Marker Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Marker Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Marker Therapeutics shares will generate the highest return on investment. By understating and applying Marker Therapeutics stock market price indicators, traders can identify Marker Therapeutics position entry and exit signals to maximize returns.
Marker Therapeutics Return and Market Media
The median price of Marker Therapeutics for the period between Thu, Aug 29, 2024 and Wed, Nov 27, 2024 is 3.18 with a coefficient of variation of 16.78. The daily time series for the period is distributed with a sample standard deviation of 0.55, arithmetic mean of 3.27, and mean deviation of 0.47. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Acquisition by Kim Anthony H. of 150512 shares of Marker Therapeutics subject to Rule 16b-3 | 09/13/2024 |
2 | Acquisition by Eansor Norman David of 14285 shares of Marker Therapeutics at 17.5 subject to Rule 16b-3 | 09/26/2024 |
3 | Omega Therapeutics stock hits 52-week low at 1.2 - Investing.com | 09/30/2024 |
4 | Acquisition by Kim Anthony H. of 160000 shares of Marker Therapeutics at 3.29 subject to Rule 16b-3 | 10/04/2024 |
5 | Acquisition by Kim Anthony H. of 160000 shares of Marker Therapeutics at 0.46 subject to Rule 16b-3 | 10/11/2024 |
6 | US Penny Stocks To Consider In October 2024 | 10/23/2024 |
7 | Marker Therapeutics Inc Q3 2024 Earnings EPS of -0.26, Revenue Surpasses Estimates at 1. ... | 11/14/2024 |
8 | Marker Therapeutics gets 2M NIH grant for MT-601 Phase 1 study - MSN | 11/22/2024 |
About Marker Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Marker or other stocks. Alpha measures the amount that position in Marker Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2022 | 2023 | 2024 (projected) | Graham Number | 26.61 | 13.75 | 7.56 | 7.19 | Receivables Turnover | 5.2K | 3.75 | 3.22 | 3.06 |
Marker Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Marker Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Marker Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Marker Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Marker Therapeutics. Please utilize our Beneish M Score to check the likelihood of Marker Therapeutics' management manipulating its earnings.
| 27th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Build Portfolio with Marker Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Marker Stock Analysis
When running Marker Therapeutics' price analysis, check to measure Marker Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marker Therapeutics is operating at the current time. Most of Marker Therapeutics' value examination focuses on studying past and present price action to predict the probability of Marker Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marker Therapeutics' price. Additionally, you may evaluate how the addition of Marker Therapeutics to your portfolios can decrease your overall portfolio volatility.